KEYNOTE-365 cohort A updated results: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Evan Y. Yu, Josep M. Piulats, Gwenaelle Gravis, Brigitte Laguerre, Jose Angel Arranz Arija, Stephane Oudard, Peter C.C. Fong, Michael Paul Kolinsky, Marinela Augustin, Susan Feyerabend, Audrey E. Kam, Howard Gurney, Ali Tafreshi, Margitta Retz, William R. Berry, Nataliya Mar, Helen Wu, Charles Schloss, Christian Heinrich Poehlein, Johann S. De Bono
Institutions: University of Washington, Institut Català d'Oncologia, Institut Paoli-Calmettes, Centre Eugène Marquis, Hospital General Universitario Gregorio Marañón, Hôpital Européen Georges-Pompidou, Auckland City Hospital, Cross Cancer Institute, Paracelsus Medizinische Privatuniversität, Rush University Medical Center, Macquarie University, University of Wollongong, TUM Klinikum, Technical University of Munich, Merck & Co., Inc., Rahway, NJ, USA (United States), Royal Marsden Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3006844234